Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

August 23, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Advanced Solid Tumors
Interventions
DRUG

HRS-1167

Participants will receive HRS-1167.

Trial Locations (20)

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

110001

RECRUITING

The First Hospital of China Medical University, Shenyang

110042

RECRUITING

Liaoning Cancer Hospital, Shenyang

130021

RECRUITING

The First Hospital of Jilin University, Changchun

150081

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

210029

RECRUITING

The First Affiliated Hospital with Nanjing Medical University, Nanjing

250062

RECRUITING

Qilu Hospital of Shandong University, Jinan

250117

RECRUITING

Shandong Cancer Hospital, Jinan

300060

RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjin

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

330209

RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

400030

RECRUITING

Chongqing Cancer Hospital, Chongqing

410013

RECRUITING

Hunan Cancer Hospital, Changsha

RECRUITING

Hunan Cancer Hospital, Changsha

450008

RECRUITING

Henan Cancer Hospital, Zhengzhou

510120

RECRUITING

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou

530021

RECRUITING

Guangxi Medical University Affiliated Tumor Hosipital, Nanning

646099

RECRUITING

The Affiliated Hospital of Southwest Medical University, Luzhou

030001

RECRUITING

Second Hospital of Shanxi Medical University, Taiyuan

030013

RECRUITING

Shanxi Provincial Cancer Hospital, Taiyuan

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY